NEW YORK – The US Food and Drug Administration has updated its requirements for molecular diagnostic developers seeking Emergency Use Authorization for COVID-19 tests to include the use of actual positive specimens.
In the eighth of its weekly virtual town hall meetings on Wednesday, Timothy Stenzel, director of the agency's office if in vitro diagnostics and radiological health, said going forward FDA will require developers to use such specimens as part of the validation process.